Advanced Solid Tumors — Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors
Citation(s)
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of BIIB021 Administered Once or Twice Daily to Subjects With Advanced Solid Tumors